Onsdag 30 Oktober | 09:26:04 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2025-05-20 09:00 Kvartalsrapport 2025-Q1
2025-05-20 - Årsstämma
2025-02-25 08:00 Bokslutskommuniké 2024
2024-11-19 09:00 Kvartalsrapport 2024-Q3
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-22 - X-dag ordinarie utdelning SYNT 0.00 SEK
2024-05-21 - Årsstämma
2024-05-21 - Kvartalsrapport 2024-Q1
2024-02-20 - Extra Bolagsstämma 2024
2024-02-20 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-22 - Kvartalsrapport 2023-Q2
2023-05-24 - X-dag ordinarie utdelning SYNT 0.00 SEK
2023-05-23 - Årsstämma
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-15 - Bokslutskommuniké 2022
2022-11-16 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-11 - X-dag ordinarie utdelning SYNT 0.00 SEK
2022-05-10 - Kvartalsrapport 2022-Q1
2022-05-10 - Årsstämma
2022-03-29 - Extra Bolagsstämma 2022
2022-02-22 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-07-13 - Kvartalsrapport 2021-Q2
2021-05-20 - Split SYNT 1:10
2021-05-12 - X-dag ordinarie utdelning SYNT 0.00 SEK
2021-05-11 - Årsstämma
2021-05-11 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-10-02 - X-dag ordinarie utdelning SYNT 1.50 SEK
2020-07-14 - Kvartalsrapport 2020-Q2
2020-05-05 - Årsstämma
2020-05-05 - Kvartalsrapport 2020-Q1
2020-02-27 - Bokslutskommuniké 2019
2019-11-12 - Kvartalsrapport 2019-Q3
2019-07-14 - Kvartalsrapport 2019-Q2
2019-04-30 - X-dag ordinarie utdelning SYNT 1.50 SEK
2019-04-29 - Kvartalsrapport 2019-Q1
2019-04-29 - Årsstämma
2019-02-27 - Bokslutskommuniké 2018
2018-11-16 - Kvartalsrapport 2018-Q3
2018-08-22 - Kvartalsrapport 2018-Q2
2018-04-26 - X-dag ordinarie utdelning SYNT 0.00 SEK
2018-04-25 - Kvartalsrapport 2018-Q1
2018-04-25 - Årsstämma
2018-02-21 - Bokslutskommuniké 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-08-24 - Kvartalsrapport 2017-Q2
2017-04-26 - X-dag ordinarie utdelning SYNT 0.00 SEK
2017-04-25 - Årsstämma
2017-04-25 - Kvartalsrapport 2017-Q1
2017-02-15 - Bokslutskommuniké 2016
2016-10-28 - Kvartalsrapport 2016-Q3
2016-08-26 - Kvartalsrapport 2016-Q2
2016-04-27 - X-dag ordinarie utdelning SYNT 0.00 SEK
2016-04-26 - Årsstämma
2016-04-26 - Kvartalsrapport 2016-Q1
2016-02-26 - Bokslutskommuniké 2015
2015-10-30 - Kvartalsrapport 2015-Q3
2015-08-28 - Kvartalsrapport 2015-Q2
2015-04-13 - Årsstämma
2015-04-13 - Kvartalsrapport 2015-Q1
2015-02-17 - X-dag ordinarie utdelning SYNT 0.00 SEK
2015-02-13 - Bokslutskommuniké 2014
2014-11-28 - Kvartalsrapport 2014-Q3
2014-09-26 - Extra Bolagsstämma 2014
2014-08-29 - Kvartalsrapport 2014-Q2

Beskrivning

LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
SyntheticMR är ett medicinteknik-bolag som är verksamt inom utveckling av analys - och avbildningsmetoder. Tekniken används huvudsakligen för magnetisk resonanstomografi (MR) inom sjukvården. Tekniken baseras på kvantifieringsbaserad metod som ämnar öka effektiviteten och kvalitén i nuvarande MR-undersökningar. Bolaget etablerades under 2007 och har sitt huvudkontor i Linköping.
2023-05-23 08:08:08

First quarter in brief
 

  •  Net sales amounted to 16,1 million SEK (9,9), which means a sales growth of 63 percent.
  • Operating profit amounted to -2 million SEK (-3,6), corresponding to an operating margin of -13 percent (-37).
  • Net profit for the period amounted to -2,2 million SEK (-3,5).
  • Earnings per share amounted to -0.05 SEK (-0.08).

Significant events during the first quarter

During the first quarter SyMRI received regulatory approval in Singapore, UK and Canada.

Significant events after the first quarter

Nothing to report.

CEO comments

Sales and cost development in line with the growth plan

Sales in the quarter amounted to SEK 16.1m (9.9). The outcome is a record for a first quarter and corresponds to an organic growth of 63 percent compared to the same period last year. Sales development mainly consists of larger orders from partners and increased direct sales. Operating profit amounted to SEK -2.0m (-3.6). This corresponds to a margin of -13 percent (-37). The development is explained by the fact that sales increased more than costs during the quarter. The cost increase compared to the same period last year stems from planned investments in line with our growth plan. As previously communicated, we have now reached a level of costs that is reasonable and relevant to our business model from which we now continue to grow with an increased focus on profitability. The outcome in the first quarter is in line with our plan and we reiterate that we expect revenues in excess of SEK 90.0m and an operating margin after depreciation of at least 20% in 2023.

The financial impact of the business and price model

With undiminished force we continue to establish SyMRI as a standard of care. The business model we developed includes sales directly to end customers and to MR system manufacturers. Over time, sales increase to both segments and in more geographic markets. The pricing model we have implemented includes options for a permanent license and now also time-limited variants. Of course, we always make an overall assessment of each deal. Among other things, any counterparty risk is evaluated and if we consider it relevant, we make applicable reservations. In addition to the above, we take the license period into account in our pricing. We too are affected by the pressure of inflation and our customers are increasingly aware of this reality with price increases as a result. The fact that with this model we tie up more capital than before is a natural consequence, which also means that we have a greater focus on cash flow. Increased capital bidding primarily applies to licenses for customers who have already installed an MR system. An example could be a sale of a five-year license to such a customer. In this case, the agreement is made with the customer that payment must be made over the license period. After applicable reservations, the income is booked, and invoicing is done from the start of the first year and thereafter evenly over the license period.

Looking ahead

SyntheticMR is well equipped to reach the goals we have set for 2023. The response from the market for SyMRI and the value the product provides to the customer is positive. The installed base we have is still negligible in terms of market share. The organization is sufficient to provide growing direct sales with increased efficiency and results. The sales organization has been expanded over several years and its efficiency has potential for improvement. The same applies to our innovative work in research and development. We are satisfied with the geographical priorities that have been made in terms of market areas. As we increase our sales, we also broaden our presence. Nowadays, we have three established subsidiaries. During the first quarter, SyMRI was approved for clinical use in three new countries. Canada, UK and Singapore are markets with high potential that provide good conditions for increased market penetration globally. We also see that our partner collaborations develop and deepen. These also facilitate the likelihood that we will achieve continued market success. The global license and distribution agreements we have strengthen our direct sales capacity. Our collaborations around product development continue successfully. Regardless of financial goals, we are driven by the ambition to successfully establish SyMRI as a standard of care. If we succeed, financial rewards will follow.

Ulrik Harrysson

CEO, SyntheticMR AB (publ)

This is a translation of the Swedish version of the report. When in doubt, the Swedish wording prevails.
 

This disclosure contains information that SyntheticMR AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-05-2023 08:08 CET.